Core Viewpoint - The article discusses the potential for Chinese innovative drugs to achieve significant breakthroughs in 2025, highlighting a notable transaction involving 1.25 billion USD upfront payment and a total deal value of 6.05 billion USD for a PD-1/VEGF dual antibody sold by 3SBio to Pfizer, indicating a shift in the global pharmaceutical landscape towards Chinese innovations [1]. Group 1 - The transaction marks a significant increase in the value of Chinese innovative drugs, with the upfront payment amount increasing 50 times compared to a similar deal a decade ago [1]. - The global pharmaceutical giants are now competing for next-generation PD-1 antibody technologies, with high-quality assets predominantly held in China [1]. - The article suggests that the Chinese innovative drug sector is entering a "big outbound" era, reflecting a revaluation of its worth in the global market [1].
60亿美元，又一单！ 中国创新药“大出海”
21世纪经济报道·2025-06-08 15:53